Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201775 | 0.92 | ALDH1A1 (0.64) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL2360974 | 0.90 | ALDH1A1 (0.84) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL5347059 | 0.87 | ALDH1A1 (0.97) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL28137833 | 0.86 | ALDH1A1 (1.00) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL7589283 | 0.85 | POLB (0.64) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL7589260 | 0.85 | POLB (0.64) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL7647475 | 0.84 | ALDH1A1 (0.75) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL9976087 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL2061369 | 0.83 | PKM (0.76) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL2062534 | 0.83 | POLB (0.75) | ALDH1A1LMNAPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3044218-A2 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | Board Of Regents Of the University Of Texas System (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | ALDH1A1 4595/4885LMNA 891/4885PKM 3091/4885 |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | ALDH1A1 4595/4885LMNA 891/4885PKM 3091/4885 |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | ALDH1A1 4595/4885LMNA 891/4885PKM 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.